RSRusana R. Samigullina

Rusana R. Samigullina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rusana R. Samigullina has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacoeconomic study of tocilizumab dosing strategies as an intravenous solution in rheumatoid arthritis

    by A. M. Lila, A. A. Vasilenko, E. V. Gerasimova, A. I. Dubikov, A. I. Zagrebneva, E. V. Zonova, L. V. Ivanova, T. N. Kargaeva, M. A. Korolev, A. I. Kulikov, et al.

    Tocilizumab (TCZ) is widely used in rheumatoid arthritis (RA) and may be administered using different dosing regimens, including the standard dose (SD) of 8 mg/kg and regimens involving dose reduction or escalation depending on the clinical response. Under current healthcare conditions, assessment of the clinical and economic feasibility of drug-dosing strategies is particularly relevant. Objective : to evaluate, from the perspective of the Russian healthcare system, the clinical and economic feasibility of a TCZ dose de-escalation strategy (DDS) from 8 to 4 mg/kg after remission is achieved and a dose escalation strategy (DES) from 4 to 8 mg/kg if remission is not achieved, compared with the SD of 8 mg/kg in patients with RA. Material and methods . A decision-tree model with 1and 3-year time horizons was developed to compare the three TCZ dosing strategies. Costminimization analysis, budget impact analysis, and one-way sensitivity analysis were performed. Results and discussion . Over a 1-year time horizon, DES provided savings of 169,850 rubles (28.1%) per patient compared with SD, whereas DDS provided savings of 58,188 rubles (9.6%). Over a 3-year time horizon, savings amounted to 168,849 rubles (10.3%) and 95,848 rubles (5.8%) for DES and DDS, respectively. According to the budget impact analysis, transferring a proportion of patients to DES could reduce costs by 1.0–1.7 billion rubles over 3 years, whereas transition to DDS could reduce costs by 0.6–1.0 billion rubles. Conclusion . Within the adopted assumptions, the model demonstrates a potential reduction in direct drug costs when using strategies involving controlled dose reduction or initiation at a lower dose followed by escalation. Owing to the limited availability of direct comparative data and regulatory restrictions in the Russian Federation, the results should be regarded as a scenario-based pharmacoeconomic assessment requiring validation using Russian data.

  • Open Access

    Non-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part

    by T. V. Dubinina, A. M. Lila, E. M. Agafonova, I. A. Andrianova, E. V. Ilyinykh, E. V. Kvasova, L. V. Ivanova, S. A. Lapshina, Yu. Yu. Grabovetskaya, I. V. Vinogradova, et al.

    In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.

  • Russian interdisciplinary consensus on the definitions of “difficult-to-manage” and “difficult-to-treat” psoriatic arthritis/psoriasis and the management of these patients

    by A. M Lila, T. V. Korotaeva, L. S. Kruglova, E. Yu. Loginova, Yu. L. Korsakova, E. E. Gubar, I. M. Patrikeeva, P. A. Shesternya, Z. Yu. Mutovina, A. I. Zagrebneva, et al.

  • General concepts of refractory and difficult-to-treat rheumatoid arthritis definitions

    by Zagrebneva A.I. Zagrebneva, Simonova E.N. Simonova, GavrikovA Yu.A. GavrikovA, Dolgov V.V. Dolgov V, Samigullina R.R. Samigullina, Mazurov V.I. Mazurov

  • Impact of the extraarticular manifestations on the efficacy and tolerability of seniprutug in radiographic axial spondyloarthritis: post hoc analysis of ELEFTA clinical trial

    by A. M. Lila, V. I. Mazurov, I. Z. Gaydukova, T. V. Dubinina, A. A. Klimenko, M. A. Korolev, S. A. Lapshina, R. R. Samigullina, E. L. Nasonov, G. A. Vinderskaya, et al.

    Objective : to assess the impact of extra-articular manifestations (EAM) on the achievement of clinical effect of seniprutug (SENI) in patients with active radiographic axial spondyloarthritis (r-axSpA) during 48 weeks of therapy. Material and methods . A post hoc analysis of results from an international multicenter randomized placebo-controlled phase II clinical trial (CT) BCD-180-2/ELEFTA (ClinicalTrials.gov NCT05445076) involving HLA-B27 positive biologic-naive patients with active r-axSpA was conducted. The main results of the CT ELEFTA on the clinical efficacy and safety of SENI over 48 weeks of therapy have been previously published. A comparative post hoc analysis of SENI efficacy was conducted at week 48 in subgroups of patients with presence (n=48) and absence (n=212) of EAM, who received SENI at doses of 5 mg/kg or 7 mg/kg or Placebo/SENI 5 mg/kg. Efficacy parameters included dynamics in the ASDAS, BASFI, as well as total back pain intensity and night back pain scores on a numerical rating scale (NRS), and C-reactive protein (CRP) levels. Additionally, the frequency of achieving ASAS40, ASAS5/6 responses, ASDAS clinically important improvement (ASDAS-CII), and low disease activity or inactive disease according to ASDAS was analyzed. The assessment of treatment tolerability included analysis of the frequency of worsening of existing EAM and the occurrence of cases of EAM de novo. Results and discussion. In both subgroups of patients with and without EAM of axSpA we observed decrease of CRP level with improvement of the disease activity according to the ASDAS index and improvement of functional impairments according to the BASFI index, as well as achievement of ASAS40 and ASAS5/6 responses and a reduction in of the total back pain and night back pain according to the NRS. Statistically significant superiority over placebo was demonstrated in the SENI subgroup without EAM at all efficacy parameters and at several assessment points in the SENI subgroup with EAM already in the first weeks of therapy and up to week 24. Further, the achieved clinical effect was maintained, up to week 48, in all SENI subgroups regardless of the presence of EAM, while in placebo subgroups, an increase in effect was observed due to switching to active drug therapy at week 24. In the SENI subgroup with EAM, a numerically more pronounced clinical effect was noted at the beginning of therapy without statistically significant differences compared to the SENI subgroup without EAM. In all studied subgroups, a favorable tolerability profile of SENI therapy was demonstrated. No EAM de novo was registered. Conclusion. SENI demonstrates significant stable clinical efficacy and good tolerability over 48 weeks of active r-axSpA treatment regardless of the presence or absence of EAM, with a trend to faster and more pronounced clinical effect in the first weeks of therapy in patients who had EAM.

  • Open Access

    Slowing the progression of ankylosing spondylitis during long-term therapy with netakimab: results of the international multicenter randomized double-blind phase III clinical trial BCD-085-5/ASTERA

    by V. I. Mazurov, A. M. Lila, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. V. Smirnov, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, et al.

    Objective. To evaluate the effect of long-term therapy with netakimab (NTK) on radiographic progression and reduction of inflammatory changes assessed by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS), and to identify factors influencing treatment response.Material and methods. A post hoc analysis was performed on 228 patients with active AS who received NTK for 156 weeks in the randomized clinical trial BCD-085-5/ASTERA. The proportion of patients without radiographic progression was determined, defined as an increase in the mSASSS (modified Stoke Ankylosing Spondylitis Spinal Score) of Results and discussion. Among 228 patients, 66% showed no radiographic progression and 63% had no increase in mSASSS at week 156 compared with baseline. Positive dynamics in ASspi-MRI-a and SPARCC indices were demonstrated during two years of NTK therapy, with sustained effect through week 156. In univariate logistic regression, younger age (p=0.013) and absence of syndesmophytes or spinal ankylosis at baseline (pConclusion. Long-term therapy with NTK prevents radiographic progression and reduces active inflammatory changes by MRI in the majority of AS patients, regardless of baseline clinical and demographic characteristics or prior tumor necrosis factor α inhibitor therapy.

  • Open Access

    Efficacy and safety of 24-week therapy with a monoclonal antibody to TRBV9+ T lymphocytes (seniprutug) in patients with ankylosing spondylitis: real-world data

    by E. A. Vasilenko, R. R. Samigullina, A. K. Karibova, Yu. Yu. Grabovetskaya, V. I. Mazurov, Ю. Ю. Грабовецкая

    In April 2024, the first biologic agent (seniprutug) selectively targeting CD8+ T lymphocytes bearing the TRBV9 segment was approved. This novel mechanism of action potentially affects the initial immunopathologic cascade in HLA-B27-associated ankylosing spondylitis (AS). During 2024, seniprutug therapy was initiated in 9 patients with AS in the European part of Russia.Objective. To evaluate the efficacy and safety of seniprutug in patients with AS at 12 and 24 weeks (3 and 6 months) in real-world clinical practice.Material and methods. Nine patients with AS were included: 7 men (77.8%) and 2 women (22.2%); mean age 37.3±12.6 years. AS was diagnosed according to ASAS (2009) and the modified New York criteria (1984). Active sacroiliitis on magnetic resonance imaging (MRI) was present in 8 patients (88.9%); spondylitis in at least one spinal segment in 7 (77.8%), with bone-marrow edema (MRI-confirmed spondylitis) in 6 (66.7%). Baseline disease activity was high: Ankylosing Spondylitis Disease Activity Score (ASDAS) 3.83±0.53; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 5.7±2.01; inflammatory markers were elevated: C-reactive protein (CRP) 49.6±36.7 mg/L (>5 mg/L in 8 patients) and erythrocyte sedimentation rate (ESR) 56.4±28.5 mm/h (>15 mm/h in all patients). Intravenous seniprutug infusions were administered at weeks 0 and 12. Complete 12- and 24-week follow-up data were available for all 9 patients by September 2025.Results and discussion. At week 12, 8 from 9 patients reported subjective improvement. Mean activity scores decreased: ASDAS to 2.57±0.94 and BASDAI to 3.41±1.17. CRP and ESR declined to 26.79±46.35 mg/L and 25.7±29 mm/h, respectively; normalization of laboratory indices occurred in 55.6% of patients. Low disease activity by ASDAS and BASDAI was recorded in 33.3% and 77.8% of cases, respectively. At week 24, 8 of 9 patients (88.9%) achieved ASAS40 response; mean ASDAS was 1.59±0.21 and BASDAI 1.75±0.81. Mean reductions were ΔASDAS (weeks 0–24) 2.42±0.75 and ΔBASDAI (weeks 0–24) 4.24±2.0. In all patients completing follow-up, inflammatory markers markedly decreased (CRP 3.4±2.3 mg/L; ESR 11.6±7.2 mm/h). One non-responder was switched to an alternative biologic DMARD.Conclusion. This first real-world study demonstrates significant clinical and laboratory improvement in AS patients treated with seniprutug. The 24-week data support the potential of this approach to modulate the pathogenic cascade in HLA-B27-associated AS and justify further evaluation in larger cohorts.

  • Open Access

    Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study

    by Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Yu. Davidian, O. E. Epifanova, N. A. Kiryukhina, L. V. Masneva, et al.

    Under real-world clinical practice together with indices for assessing disease activity and the effectiveness of therapy, drug retention provides critical information on efficacy, safety, compliance and convenience of use.The aim – to obtain data on the safety of netakimab (NTK) in a population of patients with ankylosing spondylitis (AS), including various somatic diseases, as well as to assess retention on therapy during 2 years of observation in real word clinical practice.Materials and methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included 137 patients who were prescribed netakimab therapy before enrollment. Clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, 52, 76, 104 weeks of therapy were collected within the study. The average age of the patients 42,3 y. O., 34.3% of them with previous biologics therapy.Results. Median observation period was 104 weeks (range 1–137 weeks). At the end of the analyzed period (104 weeks of therapy), 85,5% [95% confidence interval (95% CI): 79.7–91.8] of patients continued treatment with Netakimab. Retention on NTK therapy was slightly better in “bio-naïve” vs patients who received biologics earlier: 88.7% (95% CI: 82.3–95.5) and 78.9% (95% CI: 67.5–92.2), respectively, without significant differences between groups (p=0.16). 21 (15.3%) patients withdrew from study before visit 6. The main end of study reasons was lost to follow-up – 7 (5.1%) patients, and treatment inefficacy – 6 (4.4%) patients. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein) showed statistically significant decreases from baseline: by three times during the first 3 months of therapy and two times decrease during the first year of treatment. This trend continued in the second year of treatment, although with a lower rate of reduction. By week 104 of therapy, 52.9% (95% CI: 47.3–58.4) reached low disease activity (1.3≤ASDASConclusions. In real-world clinical practice, 85.5% of patients continued treatment with Netakimab at the end of 104 weeks. By 104 weeks 74% patients had low disease activity or inactive disease. Netakimab was well tolerated by most of patients.


  • Open Access

    Initiating targeted therapy according to EULAR recommendations in patients with inflammatory joint diseases and a history of malignancy

    by E. A. Trofimov, V. I. Mazurov, A. M. Lila, R. R. Samigullina, S. A. Makhortova, A. S. Trofimova

    The potential link between targeted therapies and malignancies (MN) in patients with inflammatory joint diseases and a history of MNs remains a frequent concern in routine rheumatological practice.In 2024, the EULAR (European Alliance of Associations for Rheumatology) task force formulated five overarching principles and seven hypotheses regarding the initiation of targeted therapy in patients with active arthritis and MN in remission, as well as one hypothesis for patients with active arthritis who have not achieved remission of the oncological disease.Key considerations included: a) the necessity of assessing the individual risk of cancer recurrence based on patient-specific factors, the type of MN, and the underlying disease; b) the importance of close cooperation with oncology specialists and determining the therapeutic strategy through shared decision-making between the patient and rheumatologist; c) the need for the timely initiation of appropriate targeted arthritis therapy in patients with cancer remission; d) a recommendation to use Janus kinase inhibitors and abatacept cautiously and only when no alternatives are available, due to the lack of data on their use in patients with prior MN.These guidelines identify specific points that require particular attention when prescribing targeted therapy to patients with active arthritis and a history of MN.

  • The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA

    by E. L. Nasonov, V. I. Mazurov, A. M. Lila, T. V. Dubinina, I. Z. Gaidukova, S. A. Lapshina, A. A. Klimenko, D. V. Somov, S. A. Lukyanov, D. M. Chudakov, et al.

    The study aims to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of seniprutug (BCD-180) in patients with active radiographic axial spondyloarthritis (r-axSpA, or ankylosing spondylitis). . Two hundred sixty patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups to receive either seniprutug (BCD-180) 5 or 7 mg/kg, or placebo. BCD-180 was administered in the respective group dose using a 0–12–36 week regimen. The placebo group patients were switched to BCD-180 5 mg/kg at Week 24, with therapy continued at Week 36. The primary endpoint was the proportion of patients achieving 40% improvement in the Assessment in Spondyloarthritis International Society (ASAS40) score at Week 24. The secondary endpoints included the proportion of patients achieving an ASAS20/40 response, improvement in 5 of 6 ASAS criteria (ASAS5/6), partial remission according to ASAS, ASDAS-CRP clinically important improvement in (Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, ASDAS-CII) and ASDAS-CRP major improvement (ASDAS-MI). An analysis of changes over time in the disease activity status according to ASDAS-CRP, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, as well as changes over time in laboratory markers (CRP and erythrocyte sedimentation rate (ESR)) was also conducted. Safety was assessed based on the frequency and profile of adverse events (AE) and adverse reactions (AR). The proportion of patients who achieved an ASAS40 response at Week 24 on seniprutug (BCD-180) at doses of 7 and 5 mg/kg was 51.4 and 40.8%, respectively, compared with 24% in the Placebo group (p = 0.0012 and p = 0.0417, respectively). Analysis of secondary endpoints showed that the efficacy of BCD-180 at both study doses was statistically significantly superior to placebo in patients with r-axSpA at Week 24 in the following respects: reduction in the proportion of subjects with very high disease activity (ASDAS-CRP > 3.5), achieving ASDAS-CII, ASAS20, ASAS5/6 response. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI score, as well as CRP and ESR levels was demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. The most common AEs were infusion-related reactions, most of which were mild to moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed mainly during the first administration. The proportion of patients with detected binding antibodies was 5.1%. No neutralizing antibodies were detected. . Seniprutug (BCD-180) as a therapy for r-axSpA has demonstrated superiority over placebo in the clinical efficacy, a good safety profile and low immunogenicity.